The lithium market is showing vigorous signs of recovery, with Albemarle Corporation positioned to capitalize on this emerging trend. Recent strategic moves by the specialty chemicals manufacturer and shifting commodity dynamics are generating renewed investor interest in the sector.
Market Dynamics Fuel Optimism
A significant upward revision in lithium price forecasts is driving sector-wide momentum. On October 30, 2025, JPMorgan substantially increased its spodumene projections for the 2026/2027 period to $1,100-$1,200 per ton, a notable jump from the previous $800 estimate. The bank’s long-term price outlook also strengthened, climbing from $1,100 to $1,300 per ton.
Concurrent with these revised forecasts, Chinese lithium spot prices have reached their highest level in two months. This price appreciation stems from robust demand for electric vehicle battery materials and energy storage systems, coupled with uncertainties surrounding the operational restart timeline for a major Chinese lithium mine.
Key Market Developments:
* JPMorgan raises spodumene price forecast to $1,100-$1,200 per ton
* Long-term price projection increases to $1,300
* Chinese spot prices hit two-month peak
* Strong EV battery material demand continues
Strategic Portfolio Optimization
Albemarle is strengthening its financial position through targeted divestitures. The company announced on October 27, 2025, that it would sell a 51% controlling stake in its catalyst business Ketjen to KPS Capital Partners. In a parallel transaction, Albemarle will divest its 50% interest in the Eurecat joint venture to Axens SA.
Should investors sell immediately? Or is it worth buying Albemarle?
These transactions are expected to generate approximately $660 million in pre-tax proceeds. Albemarle intends to allocate these funds toward debt reduction and general corporate purposes. While divesting majority control, the company will retain approximately 49% of Ketjen, maintaining exposure to the business’s future performance. Both transactions are scheduled for completion during the first half of 2026.
Upcoming Financial Results and Analyst Sentiment
Market attention now turns to Albemarle’s upcoming earnings release scheduled for November 5, 2025, after market close. The company will report third-quarter 2025 results, with analysts projecting a loss of $0.97 per share on revenue of $1.271 billion.
Despite anticipated quarterly challenges, several financial institutions have recently updated their outlook on Albemarle. Multiple banks, including DBS Bank, Deutsche Bank, and Royal Bank of Canada, have raised their price targets for the company. The consensus 12-month price target currently stands around $96.13.
The company continues its commitment to shareholder returns, declaring a quarterly dividend of $0.405 per share on October 27, 2025. This payment extends Albemarle’s track record of consistent dividend distributions, which now spans 32 consecutive years, demonstrating the company’s disciplined capital allocation strategy throughout market cycles.
Ad
Albemarle Stock: Buy or Sell?! New Albemarle Analysis from October 30 delivers the answer:
The latest Albemarle figures speak for themselves: Urgent action needed for Albemarle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 30.
Albemarle: Buy or sell? Read more here...











